CRISPR/Cas9 “double”-nickase mediated inactivation of hepatitis B virus replication
M Karimova, N Beschorner, W Dammermann, J Chemnitz, D Indenbirken, A Grundhoff, S Lüth, F Buchholz, J Schulze zur Wiesch, J Hauber · Zeitschrift für Gastroenterologie · 2015 · Heft 12
Bibliografische Angaben
Zusammenfassung
Background: Current antiviral therapies cannot cure hepatitis B virus (HBV) infection, since successful HBV eradication would require the inactivation of the viral genome, which primarily persists in host cells as episomal covalently closed circular DNA (cccDNA) and, to a lesser extent, as chromosomally integrated sequences. However, novel designer-enzymes, such as the CRISPR/Cas9 RNA-guided nuclease system, provide the technology for the development of advanced therapy strategies that directly at-tack the HBV genome. Methods: We report here the identification of cross-genotype conserved HBV sequences in the HbS…
